LYRA (Lyra Therapeutics) Valuation Rank


LYRA Lyra Therapeutics Inc LYRA
29 GF Score
Price $0.54
GF Value $2.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lyra Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Lyra Therapeutics Valuation Rank Related Terms

LYRA
29GF Score
Lyra Therapeutics Inc LYRA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lyra Therapeutics (LYRA) Overvalued in 2026?

Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued. The current stock price of $0.54 is trading 78.7% below its estimated GF Value™ of $2.53. GuruFocus considers Lyra Therapeutics to be Possible Value Trap.

Key valuation signals for LYRA:

  • Valuation Rank:
  • GF Value™: $2.53 vs. price of $0.54 (78.7% below fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyra Therapeutics Business Description

Address 480 Arsenal Way, Watertown, MA, USA, 02472
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
29GF Score

Get the complete analysis for LYRA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$2.53
GF Value